Press Releases

Date Title and Summary
Toggle Summary C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities
UPPSALA, Sweden , and SUNNYVALE, Calif. , Oct. 4, 2021 /PRNewswire/ -- C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed an agreement designed to enhance the Accuray   Radixact ® System's ability to treat breast cancer.
Toggle Summary French Hospital Network Unicancer Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies
More than 30 Accuray TomoTherapy® and CyberKnife® Platform Systems Are Currently in Use at Unicancer, the Largest Network of Comprehensive Cancer Centers in Europe SUNNYVALE, Calif. , Sept. 29, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Unicancer has selected
Toggle Summary Nagoya City University Hospital is First in Japan to Treat Cancer Patients Using the Accuray Radixact® System with ClearRT™ Helical Fan-Beam kVCT Imaging
SUNNYVALE, Calif. , Sept. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Nagoya City University Hospital in Aichi has treated the first cancer patient in Japan using the Radixact ® System with ClearRT ™ helical fan-beam kVCT imaging.
Toggle Summary Accuray CyberKnife® Robotic Radiotherapy Platform is Superior to Conventional Linear Accelerators in Reducing Incidence of Bladder Side Effects in Prostate Cancer Patients
- Prospective, randomized, international multicenter study - PACE - Prostate Advances in Comparative Evidence - results presented at ESTRO 2021 - Bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment
Toggle Summary Mika Nishimura Joins Accuray Board of Directors
SUNNYVALE, Calif. , Aug. 23, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021 . With Ms. Nishimura's appointment, the Accuray Board will consist of nine members. Ms.
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2021 Financial Results
SUNNYVALE, Calif. , Aug. 11, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2021 .     Q4 Fiscal 2021 and Recent Operating Highlights Gross orders of $112.7 million , an increase of 19 percent from the
Toggle Summary Hong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging
ClearRT Significantly Improves Image Quality, Facilitating the Delivery of More Precise and Accurate Treatments to Patients SUNNYVALE, Calif. , July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at Hong Kong Sanatorium & Hospital  (HKSH) in
Toggle Summary Accuray to Report Fiscal Year-End 2021 Financial Results on August 11, 2021
SUNNYVALE, Calif. , July 14, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) will report financial results for the fourth quarter and fiscal year 2021, ended June 30, 2021 , after the market close on Wednesday, August 11, 2021. Management will host a conference call to review the results
Toggle Summary Beloved Family Pet's Lung Cancer is Treated with Targeted Radiotherapy Using the Accuray Radixact® System with Synchrony® Technology
- UW-Madison School of Veterinary Medicine performed the first-in-world treatment - Renowned veterinary school leveraged the advanced Radixact and Synchrony technology, currently available at top academic hospitals, to provide the highest level of care SUNNYVALE, Calif.
Toggle Summary Accuray Announces Promotion of Suzanne Winter to President
SUNNYVALE, Calif. , June 22, 2021 /PRNewswire/ --  Accuray (NASDAQ: ARAY) announced today that Suzanne Winter has been promoted to president, effective as of July 1, 2021 . Ms. Winter , who previously served as the company's chief commercial officer and senior vice president of R&D and medical and

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at